Ruijian Pharmaceutical Bags ￥10M in Pre-A Round

According to VCBeat, Wuhan Ruijian Pharmaceutical Technology Co., Ltd. ("Ruijian Pharmaceutical"), a leading company in the development of drugs from chemically induced adult stem cells, announced the completion of ￥10M Pre-A round of financing, jointly invested by Renfu Industry Fund and Huafang Capital. Proceeds will be used for the safety evaluation and IND application of NouvNeu001, Ruijian Pharmaceutical’s first pipeline of Parkinson.

Ruijian Pharmaceutical is a cellular drug company focused on solving unmet medical needs. Using its unique small molecule libraries and living cells real-time reporting platform, Ruijian Pharmaceutical has developed multiple cellular drug pipelines by chemical induction, covering the treatment of cell regeneration neurodegenerative diseases, metabolic system diseases, rare diseases, and others.

Ruijian Pharmaceutical was founded by returned scholars from The University of Cambridge in August 2017. The two founders have more than 10 years of successful experience overseas in the development of cellular drugs and nucleic acid drugs respectively.

In January 2019, Ruijian Pharmaceutical completed the angel round financing led by Huafang Capital with participation from Optical Valley Talent Fund. At present, Ruijian Pharmaceutical has completed the construction of the GMP cell seed stock, more than 100 kinds of chemical-inducing small molecule banks, iPSC/ESC differentiation system, and the improvement of the non-stem cell conversion system. Its first pipeline NouvNeu001 has achieved excellent therapeutic results in the primate model of Parkinson's disease. The company has finished the pilot production of NouvNeu001.

In 2013, Renfu Pharma established a professional VC/PE management company, initiated pharmaceutical industry funds, and take full use of the advantages of industrial investors who have invested or operated in pharmaceutical firms for more than a decade, building a professional investment and research teams with rich experience.

Huafang Capital is focused on biomedical investment in the field of big health, specifically in biopharmaceutical, high-end medical devices, medical services, medical informatization and other segments. At present, it has completed the investment of a number of leading enterprises in those field.